Pembrolizumab provides long‐term survival benefits in advanced non‐small cell lung cancer: The 5‐year outcomes of the KEYNOTE‐024 trial

Detalles Bibliográficos
Autores principales: Li, Fengtan, Dong, Xifeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636217/
https://www.ncbi.nlm.nih.gov/pubmed/34643064
http://dx.doi.org/10.1111/1759-7714.14193
_version_ 1784608490264723456
author Li, Fengtan
Dong, Xifeng
author_facet Li, Fengtan
Dong, Xifeng
author_sort Li, Fengtan
collection PubMed
description
format Online
Article
Text
id pubmed-8636217
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-86362172021-12-08 Pembrolizumab provides long‐term survival benefits in advanced non‐small cell lung cancer: The 5‐year outcomes of the KEYNOTE‐024 trial Li, Fengtan Dong, Xifeng Thorac Cancer Commentary John Wiley & Sons Australia, Ltd 2021-10-13 2021-12 /pmc/articles/PMC8636217/ /pubmed/34643064 http://dx.doi.org/10.1111/1759-7714.14193 Text en © 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Commentary
Li, Fengtan
Dong, Xifeng
Pembrolizumab provides long‐term survival benefits in advanced non‐small cell lung cancer: The 5‐year outcomes of the KEYNOTE‐024 trial
title Pembrolizumab provides long‐term survival benefits in advanced non‐small cell lung cancer: The 5‐year outcomes of the KEYNOTE‐024 trial
title_full Pembrolizumab provides long‐term survival benefits in advanced non‐small cell lung cancer: The 5‐year outcomes of the KEYNOTE‐024 trial
title_fullStr Pembrolizumab provides long‐term survival benefits in advanced non‐small cell lung cancer: The 5‐year outcomes of the KEYNOTE‐024 trial
title_full_unstemmed Pembrolizumab provides long‐term survival benefits in advanced non‐small cell lung cancer: The 5‐year outcomes of the KEYNOTE‐024 trial
title_short Pembrolizumab provides long‐term survival benefits in advanced non‐small cell lung cancer: The 5‐year outcomes of the KEYNOTE‐024 trial
title_sort pembrolizumab provides long‐term survival benefits in advanced non‐small cell lung cancer: the 5‐year outcomes of the keynote‐024 trial
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636217/
https://www.ncbi.nlm.nih.gov/pubmed/34643064
http://dx.doi.org/10.1111/1759-7714.14193
work_keys_str_mv AT lifengtan pembrolizumabprovideslongtermsurvivalbenefitsinadvancednonsmallcelllungcancerthe5yearoutcomesofthekeynote024trial
AT dongxifeng pembrolizumabprovideslongtermsurvivalbenefitsinadvancednonsmallcelllungcancerthe5yearoutcomesofthekeynote024trial

Ejemplares similares